Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc. is experiencing an increased confidence in its product candidate, KYV-101, particularly in the treatment of Myasthenia Gravis (MG), with a raised probability of approval from 25% to 35%, reflecting strong clinical data on durability and response times in patients. Additionally, the company has demonstrated promising results for KYV-101 across multiple autoimmune conditions, including rheumatoid arthritis (RA), where data suggests its efficacy surpasses existing therapies like rituximab. Overall, the augmenting clinical evidence and growing recognition of KYV-101's capabilities in various indications contribute positively to its long-term financial outlook and market potential.

Bears say

Kyverna Therapeutics faces significant challenges that raise concerns about its financial outlook, primarily due to the lack of durable responses observed in patients treated with its lead product candidate, KYV-101, particularly in lupus nephritis (LN) and myasthenia gravis (MG). Additionally, the potential failure to generate favorable data for KYV-101 in secondary progressive multiple sclerosis (SPS) further compounds the uncertainties surrounding its product pipeline. Lastly, the prospect of long-term dilution risk presents further financial instability, which could negatively impact shareholder value and investor confidence.

KYTX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 3 analysts, KYTX has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.